Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Current dialysis patients face a demanding routine of thrice-weekly, four-hour sessions, accompanied by blood pressure fluctuations and strict fluid restrictions. While artificial kidneys have been studied to fully replicate renal function, reproducing both the filtration of 200 L of fluid per day and tubular reabsorption remains extremely challenging.
We propose a hybrid renal replacement therapy combining an implantable hemofiltration device with conventional dialysis. The implanted device continuously removes an appropriate amount of fluid, maintaining stable body fluid volume and allowing patients to drink an equivalent amount of water (designed at 1.5 L/day). As a result, dialysis frequency can be reduced according to residual kidney function, improving both quality of life and clinical outcomes.
Our hemofiltration device operates under natural blood pressure without an external pump. A 10-day in vivo goat experiment successfully demonstrated the feasibility of this concept.
The hemofiltration device consists of a layered filter structure composed of a polyethersulfone (PES) dialysis membrane, with alternating microchannels for blood flow and filtrate flow. The device is connected to the carotid artery and vein of a goat via artificial vascular grafts and implanted in the cervical region. During the experiment, systemic anticoagulation was maintained with heparin to keep the activated clotting time (ACT) at approximately 250 seconds. The collected filtrate confirmed that the device was functioning properly.
After the device was connected to the carotid artery and vein of the goat, filtrate was successfully obtained. The goat recovered from anesthesia and began eating a few hours later. During the first two days, the activated clotting time (ACT) exceeded 300 seconds, and the goat’s condition deteriorated. After the heparin dosage was reduced, the goat gradually recovered and showed good activity. The animal remained active throughout the 10-day experimental period, and filtrate was continuously obtained.
We designed and fabricated a hemofiltration device for hybrid renal replacement therapy. A 10-day experiment using a goat was successfully conducted, demonstrating the feasibility of the device. Longer-term in vivo experiments are planned to further evaluate its performance.
